Cara Mathews, MD, Talks Dostarlimab for Advance Recurrent Endometrial Cancers
Cara Mathews, MD, spoke with CancerNetwork® about research examining dostarlimab vs doxorubicin for patients with mismatch repair–deficient endometrial cancers.
Marina Frimer, MD, Discusses Maintenance Niraparib in Platinum-Sensitive Uterine Serous Cancer
Marina Frimer, MD, spoke about the goals of a phase 2 trial and how it can impact patients with platinum-sensitive recurrent uterine serous carcinoma.
The Influence of Risk Category Stratification Algorithms on CLEAR Trial Data
Thomas Hutson, DO, PharmD, and Scott Tykodi, MD, PhD, discuss their takeaways from the CLEAR trial and how risk category stratification affected the study.
A Physician’s Take on the CLEAR Trial Data
Brian Shimkus, MD, shares his opinion of data on lenvatinib and pembrolizumab from the CLEAR trial.
A Role for Single Agent TKI Therapies in Treating Renal Cell Carcinoma
Oncologists debate whether TKI monotherapy has a place in renal cell carcinoma treatment after the CLEAR trial.
Exciting Developments in the Pipeline in HER2+ MBC
A multidisciplinary panel of health care professionals and a patient advocate comment on their excitement about novel therapies in the pipeline for HER2-positive metastatic breast cancer.
HER2+ MBC: Radiation Necrosis Vs Disease Progression
Improvements regarding the identification and management of radiation necrosis in patients with HER2-positive metastatic breast cancer.
Presentation and Disease Course of Differentiated Thyroid Cancer
Lori Wirth, MD, provides an overview of differentiated thyroid cancer including patient presentation and disease course.
The Role of Genetic Mutations in Prognosis and Decision-Making
Chung-Han Lee, MD, PhD discusses how genetic mutations inform patient prognosis and decision-making for patients with kidney cancer.
Prognostic Value of Biomarkers in RCC
Robert Alter, MD opines on the current prognostic value of biomarkers for RCC and the need for additional data in the field.
Biomarker Testing: Methodologies, Sample Types, and Emerging Data
Mehmet Asim Bilen, MD weighs in on various biomarker testing methodologies, sample considerations, and emerging data on novel biomarkers.
Biomarker Testing in RCC: Current Approaches
David Aggen, MD, PhD reviews how he currently approaches biomarker testing in patients with RCC.
Metastatic RCC: Prognosis and Recent Advances in Care
Mehmet Asim Bilen, MD comments on the prognosis of patients with metastatic RCC and how recent advances have improved outcomes.
Risk Models and Prognostic Factors
Robert Alter, MD comments on the use of prognostic models for determining risk status and informing treatment options in patients with RCC.
Candice Roth, MSN, RN, CENP, Describes the Evolution of Electronic Treatment Pathways at Levine Cancer Institute
Candice Roth, MSN, RN, CENP, spoke about how the electronic treatment pathways have evolved over time.
Ira Winer, MD, PhD, Talks Best Data to Come Out of SGO 2022
Ira Winer, MD, PhD, FACOG, spoke about which presentations during The Society of Gynecologic Oncology 2022 Annual Meeting he most enjoyed.
Laurence Albigès, MD, PhD, on the Potential Impact of Immunotherapy-Based Combinations in Advanced RCC
Laurence Albigès, MD, PhD, discusses how immunotherapy combinations have affected the treatment landscape for previously untreated advanced or metastatic renal cell carcinoma.
Brian Slomovitz, MD, Reviews Adjuvant Pembrolizumab and Chemo +/– Radiotherapy in Endometrial Cancer
Proteasome Inhibition in MM: In-Class Transition From Bortezomib to Ixazomib
Experts Paul Richardson, MD, and Cristina Gasparetto, MD, discuss trial data analyzing the in-class transition from bortezomib to ixazomib for patients with multiple myeloma.
Choosing Appropriate Patients and Dosing for Lenvatinib + Pembrolizumab in RCC
Expert insights on selecting the appropriate patients and dose for treatment with the lenvatinib plus pembrolizumab regimen in patients with renal cell carcinoma.
